InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLF
Post# of 228
(Total Views: 879)
Posted On: 07/05/2017 6:40:01 PM
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Focused on the Science of Cannabinoids
Science-based cannabinoid pharmaceuticals are big market winners
InMed Pharmaceuticals is developing two potential blockbuster drugs
IMLFF has innovative and disruptive market advantages
The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once elicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW Pharmaceuticals (NASDAQ: GWPH), an early mover in cannabinoid pharmaceutical development. The company’s shares have exploded from less than $9 in 2013 to around $99 today because of its proven cannabis-based therapies and drug pipeline aimed at treating central nervous system (CNS) and other disorders. Cannabis-based pharmaceutical companies should be recognized as innovative pharmaceutical companies researching the significant benefits of cannabis-based therapeutics.
An extremely interesting innovator in the cannabinoid pharmaceutical space is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). InMed is a biopharmaceutical company that specializes in developing novel therapies through research into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. The company is currently developing potential blockbuster therapies for glaucoma, one of the leading causes of blindness in the U.S., and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity. Effective therapeutics for these markets are valued at $5.6 billion and $1 billion, respectively. Blockbuster attributes notwithstanding, the real value drivers for the company can be found in its research and development of the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Utilizing its proprietary computer-based bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals and cannabinoids with similar structures, InMed identifies active cannabinoids to act on genes and proteins. Using its comprehensive algorithms and extensive databases, InMed can rapidly scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s proprietary bioinformatics assessment tool creates immense opportunity for InMed’s rapid identification and development of efficacious cannabinoid therapeutics.
Even more importantly than its bioinformatics assessment tool, InMed is about to disrupt the cannabinoid pharmaceutical sector with its biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids. InMed’s biosynthesis process for manufacturing all 90+ naturally occurring cannabinoids will combine the safety, efficacy, convenience, control and quality of a laboratory-based manufacturing process. InMed’s biosynthesis process for manufacturing pharmaceutical cannabinoids could easily become the accepted standard in this new and exciting pharmaceutical arena. InMed is laser focused on the science of cannabinoids, and science, ultimately, always wins.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Science-based cannabinoid pharmaceuticals are big market winners
InMed Pharmaceuticals is developing two potential blockbuster drugs
IMLFF has innovative and disruptive market advantages
The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once elicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW Pharmaceuticals (NASDAQ: GWPH), an early mover in cannabinoid pharmaceutical development. The company’s shares have exploded from less than $9 in 2013 to around $99 today because of its proven cannabis-based therapies and drug pipeline aimed at treating central nervous system (CNS) and other disorders. Cannabis-based pharmaceutical companies should be recognized as innovative pharmaceutical companies researching the significant benefits of cannabis-based therapeutics.
An extremely interesting innovator in the cannabinoid pharmaceutical space is InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). InMed is a biopharmaceutical company that specializes in developing novel therapies through research into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. The company is currently developing potential blockbuster therapies for glaucoma, one of the leading causes of blindness in the U.S., and epidermolysis bullosa, a devastating genetic skin disease that afflicts up to 20 million newborns in varying degrees of severity. Effective therapeutics for these markets are valued at $5.6 billion and $1 billion, respectively. Blockbuster attributes notwithstanding, the real value drivers for the company can be found in its research and development of the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
Utilizing its proprietary computer-based bioinformatics assessment tool, InMed’s unique research approach can expedite identification of bioactive compounds that have the potential to significantly impact specific diseases. By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals and cannabinoids with similar structures, InMed identifies active cannabinoids to act on genes and proteins. Using its comprehensive algorithms and extensive databases, InMed can rapidly scrutinize, analyze and identify novel cannabinoids to determine potential new drug candidates that maximize therapeutic benefit and minimize adverse effects. InMed’s proprietary bioinformatics assessment tool creates immense opportunity for InMed’s rapid identification and development of efficacious cannabinoid therapeutics.
Even more importantly than its bioinformatics assessment tool, InMed is about to disrupt the cannabinoid pharmaceutical sector with its biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids. InMed’s biosynthesis process for manufacturing all 90+ naturally occurring cannabinoids will combine the safety, efficacy, convenience, control and quality of a laboratory-based manufacturing process. InMed’s biosynthesis process for manufacturing pharmaceutical cannabinoids could easily become the accepted standard in this new and exciting pharmaceutical arena. InMed is laser focused on the science of cannabinoids, and science, ultimately, always wins.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼